Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNBioSe Study
NL-OMON42194Phase 2Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and belimumab in systemic lupus erythematosus (SLE), sponsored by Leiden University Medical Center. Primary endpoints: Sustained reduction of pathogenic autoantibodies and Inhibition of NET formation. Started May 2014; status: active, not recruiting.
02
Drugs
rituximabbelimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON42194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42194.